archive-com.com » COM » A » AGENDIA.COM

Total: 235

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Molecular Portraits of Human Breast Tumours | Agendia
    treatments 1 Variation in transcriptional programs accounts for much of the biological diversity of human cells and tumours In each cell signal transduction and regulatory systems transduce information from the cell s identity to its environmental status thereby controlling the level of expression of every gene in the genome Here we have characterized variation in gene expression patterns in a set of 65 surgical specimens of human breast tumours from 42 different individuals using complementary DNA microarrays representing 8 102 human genes These patterns provided a distinctive molecular portrait of each tumour Twenty of the tumours were sampled twice before and after a 16 week course of doxorubicin chemotherapy and two tumours were paired with a lymph node metastasis from the same patient Gene expression patterns in two tumour samples from the same individual were almost always more similar to each other than either was to any other sample Sets of co expressed genes were identified for which variation in messenger RNA levels could be related to specific features of physiological variation The tumours could be classified into subtypes distinguished by pervasive differences in their gene expression patterns See article Categories Abstract Poster 18 Accreditation 1 BluePrint 9 Clinical Studies

    Original URL path: http://www.agendia.com/molecular-portraits-of-human-breast-tumours/ (2016-05-01)
    Open archived version from archive


  • Abstract / Poster | Agendia
    of 25 51 208 of tumors with potential therapeutic and prognostic implications 39 of clinical HER 2 disease should have been treated with Continued PROMIS PRospective study Of MammaPrint in breast cancer patients with an Intermediate recurrence Score Publication Name Cancer Research Author s Hatem Soliman Sarah Untch Lisette Stork Sloots December 15 2012 PROMIS is a prospective study that will investigate the additional value of MammaPrint BluePrint and TargetPrint in women with an intermediate Oncotype DX score An initial CRF capturing baseline patient characteristics pathology information Oncotype DX score and the recommended Continued MINT I Multi Institutional Neoadjuvant Therapy MammaPrint Project I Publication Name Cancer Research Author s Charles Cox Peter Blumencranz Douglas Reintgen Ruben Saez Nicole Howard Jessica Gibson Lisette Stork Sloots Femke de Snoo Stefan Glu ck December 15 2012 Treatment of locally advanced breast cancer LABC with neoadjuvant chemotherapy measures the in vivo response to chemotherapy 1 assesses long term clinical outcomes associated with that response2 3 and enables some patients to undergo breast conservation therapy due to therapeutic down staging of the tumor In the current study the Continued Gene expression profiling to predict the risk of locoregional recurrence in breast cancer Publication Name Cancer Research Author s C A Drukker M V Nijenhuis S G Elias J Wesseling N S Russell P Whitworth R Patel F de Snoo L J van t Veer P D Beitsch E J Th Rutgers December 15 2012 The 70 gene signature is able to predict the risk of locoregional recurrence We observed a significantly lower incidence of locoregional recurrence in patients with a low risk 70 gene signature result compared to those with high risk 70 gene signature result independent Continued Comparison of molecular BluePrint MammaPrint and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041 BIG 3 04 MINDACT trial Publication Name SABCS 2012 Poster Author s Giuseppe Viale Leen Slaets Femke de Snoo Laura J van t Veer Emiel J Rutgers Martine Piccart Jan Bogaerts Jeroen van den Akker Lisette Stork Sloots Kristel Engelen Leila Russo Patrizia Dell Orto Fatima Cardoso December 6 2012 Biology has become the main driver of breast cancer therapy Intrinsic biological subtypes by gene expression profiling have been identified Pathology can be used to define surrogates of these subtypes but these are not always concordant which may lead to Continued Clinical and technical validation of a genomic classifier ColoPrint for predicting outcome of patients with stage II colon cancer Publication Name 2012 ASCO Gastrointestinal Cancers Symposium JCO Abstract Author s Josep Tabernero Victor Moreno Robert Rosenberg Ulrich Nitsche Thomas Bachleitner Hofmann Giovanni Lanza Jeroen van den Akker Paul Roepman Iris Simon Ramon Salazar Vall d Hebron University Hospital Barcelona Spain IDIBELL Institut Catala d Oncologia L Hospitalet de Llobregat Spain Department of Surgery Klinikum Rechts der Isar Technische Universität München Munich Germany Medizinische Universitaet Wien Vienna Austria Department of Experimental and Diagnostic Medicine Section of Anatomic Pathology Ferrara Italy Agendia BV Amsterdam Netherlands Institut Catala d

    Original URL path: http://www.agendia.com/category/abstract-poster/ (2016-05-01)
    Open archived version from archive

  • Accreditation | Agendia
    THE NETHERLANDS August 20 2012 Agendia an innovative molecular cancer diagnostics company and leader in personalized medicine today announced that it has been granted the International Organization for Standardization ISO 13485 certification for all activities Continued Categories Abstract Poster 18 Accreditation 1 BluePrint 9 Clinical Studies 8 ColoPrint 5 Cost Effectiveness 6 Development 8 Impact Study 2 MammaPrint 40 MINDACT 5 News 56 Predictive 3 Press Release 53 Publications 58

    Original URL path: http://www.agendia.com/category/accreditation/ (2016-05-01)
    Open archived version from archive

  • BluePrint | Agendia
    of false positive estrogen receptor status in breast cancer diagnostics Publication Name Breast Cancer Research and Treatment Author s Groenendijk Wilbert Zwart Arno Floore Stephanie Akbari Rene Bernards August 4 2013 It is well established that only estrogen receptor ER positive tumors benefit from hormonal therapies We hypothesized that a subgroup of breast cancer patients expresses estrogen receptor a ERa but fails to respond to hormonal therapy due to the expression of Continued Molecular subtyping of early stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy Publication Name Breast Cancer Research and Treatment Author s Stefan Glück Femke de Snoo Justine Peeters Lisette Stork Sloots George Somlo June 1 2013 The aim of this study was to analyze the correlation between the pathologic complete response pCR rate after neoadjuvant chemotherapy and long term outcome distant metastases free survival DMFS in patients with early stage breast cancer using BluePrint and MammaPrint molecular subtyping versus Continued Comparison of Molecular Subtyping with BluePrint MammaPrint and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients Publication Name Annals of Surgical Oncology Author s Bichlien Nguyen Pino G Cusumano Kenneth Deck Deborah Kerlin Agustin A Garcia Julie L Barone Edgardo Rivera Katharine Yao Femke A de Snoo Jeroen van den Akker Lisette Stork Sloots Daniele Generali August 15 2012 Purpose To compare breast cancer subtyping with the three centrally assessed microarray based assays BluePrint MammaPrint and TargetPrint with locally assessed clinical subtyping using immunohistochemistry IHC and fluorescence in situ hybridization FISH Methods BluePrint MammaPrint and TargetPrint were all performed on Continued A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response Publication Name Breast Cancer Research and Treatment Author s Oscar Krijgsman Paul Roepman Wilbert Zwart Jason S Carroll Sun Tian Femke A de Snoo Richard A Bender Rene Bernards Annuska M Glas July 13 2011 Classification of breast cancer into molecular subtypes maybe important for the proper selection of therapy as tumors with seemingly similar histopathological features can have strikingly different clinical outcomes Herein we report the development of a molecular subtyping profile BluePrint that Continued A gene profile that identifies molecular subtypes of breast cancer is highly enriched in genes having Estrogen Receptor binding sites Publication Name ASCO 2011 Poster Author s W Zwart F De Snoo et al June 6 2011 Classification of breast cancer into molecular subtypes may be important for the proper selection of therapy as tumors with seemingly similar biology can have strikingly different clinical outcomes We have previously developed an 80 gene molecular subtyping profile BluePrint for the classification of breast cancer into three Continued Strategies for subtypes dealing with the diversity of breast cancer highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Publication Name Annals of Oncology Author s A Goldhirsch W C Wood A S Coates R D Gelber B Thu rlimann H J Senn Panel May 23 2011 The 12th St Gallen International Breast Cancer Conference

    Original URL path: http://www.agendia.com/category/blueprint/ (2016-05-01)
    Open archived version from archive

  • Clinical Studies | Agendia
    main driver of breast cancer therapy Intrinsic biological subtypes by gene expression profiling have been identified Pathology can be used to define surrogates of these subtypes but these are not always concordant which may lead to Continued NBRST Prospective neo adjuvant registry trial linking MammaPrint subtyping and treatment response Neoadjuvant Breast Registry Symphony Trial Publication Name Cancer Research Author s Pat Whitworth Mark Gittleman Stephanie Akbari Bichlien Nguyen Paul Baron Michael Rotkiss Jennifer Beatty Jessica Gibson Lisette Stork Sloots Femke de Snoo Peter Beitsch December 15 2011 The scope of this registry study is to measure chemosensitivity as defined by pCR primary endpoint or endocrine sensitivity as defined by partial response decrease in longest tumor diameter or residual cancer burden category 1 RCB1 a primary endpoint for Continued The PARSC Trial a Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint Publication Name ASCO 2011 Poster Author s R Salazar R Rosenberg M Lutke Holzik J Marshall4 J J M Van Der Hoeven B Glimelius F Bibeau L Stork Sloots June 4 2011 Background An 18 gene expression profile ColoPrint has been developed for identifying CC patients more likely to develop recurrent disease and who would be candidates for adjuvant chemotherapy The gene signature was validated in in silico datasets and independent patient cohorts of stage Continued I SPY 2 An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy Publication Name Clinical Pharmacology Therapeutics Author s Barker AD Sigman CC Kelloff GJ Hylton NM Berry DA Esserman LJ May 13 2009 I SPY 2 investigation of serial studies to predict your therapeutic response with imaging and molecular analysis 2 is a process targeting the rapid focused clinical development of paired oncologic therapies and biomarkers The framework is an adaptive phase

    Original URL path: http://www.agendia.com/category/clinical-studies/ (2016-05-01)
    Open archived version from archive

  • ColoPrint | Agendia
    Hospital Barcelona Spain IDIBELL Institut Catala d Oncologia L Hospitalet de Llobregat Spain Department of Surgery Klinikum Rechts der Isar Technische Universität München Munich Germany Medizinische Universitaet Wien Vienna Austria Department of Experimental and Diagnostic Medicine Section of Anatomic Pathology Ferrara Italy Agendia BV Amsterdam Netherlands Institut Catala d Oncologia Barcelona Spain January 8 2012 Background Between 25 and 35 of stage II colon cancer patients will experience a relapse of their disease and may benefit from adjuvant chemotherapy ColoPrint is a gene expression classifier that can predict disease relapse in patients with early stage colorectal Continued The PARSC Trial a Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint Publication Name ASCO 2011 Poster Author s R Salazar R Rosenberg M Lutke Holzik J Marshall4 J J M Van Der Hoeven B Glimelius F Bibeau L Stork Sloots June 4 2011 Background An 18 gene expression profile ColoPrint has been developed for identifying CC patients more likely to develop recurrent disease and who would be candidates for adjuvant chemotherapy The gene signature was validated in in silico datasets and independent patient cohorts of stage Continued Independent validation of a prognostic genomic profile ColoPrint for stage II colon cancer CC patients Publication Name ASCO GI 2011 Author s R Rosenberg M Maak U Nitsche T Schuster B Kuenzli I Simon R Bender K P Janssen and H Friess January 26 2011 Background Adjuvant therapy is not routinely recommended for stage II CC patients but may be considered for high risk patients In this study we aim to independently validate a genomic profile that was developed to identify high risk patients and can assist in Continued Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer Publication Name Journal of

    Original URL path: http://www.agendia.com/category/coloprint/ (2016-05-01)
    Open archived version from archive

  • Cost Effectiveness | Agendia
    increasingly for risk stratification to identify women with lymph nodenegative estrogen receptor positive early stage breast cancer who are most likely to benefit from adjuvant chemotherapy The authors of this report evaluated the Continued Head to head comparison of the 70 gene signature versus the 21 gene assay cost effectiveness and the effect of compliance Publication Name Breast Cancer Research and Treatment Author s Valesca P Retel Manuela A Joore Wim H van Harten September 2 2011 Both the 70 gene signature and the 21 gene assay are novel prognostic tests used to guide adjuvant chemotherapy decisions in patients with early breast cancer Although the results of ongoing prospective trials will only become available in some years the tests Continued Cost Effectiveness of 70 Gene MammaPrint Signature in Node Negative Breast Cancer Publication Name The American Journal of Managed Care Author s Er Chen MPP Kuo Bianchini Tong MS and Jennifer L Malin MD PhD December 1 2010 Objective To evaluate the cost effectiveness of 70 gene MammaPrint signature Agendia Inc Huntington Beach CA vs Adjuvant Online soft ware AS http www adjuvantonline com in patients 60 years or younger with early stage breast cancer Study Design Cost effectiveness and cost utility analyses from a US Continued Cost effectiveness of the 70 gene signature versus St Gallen guidelines and Adjuvant Online for early breast cancer Publication Name European Journal of Cancer Author s Valesca Retel MA Joore WH van Harten May 1 2010 Background The 70 gene signature MammaPrint is a prognostic test used to guide adjuvant treatment decisions in patients with node negative breast cancer In order to decide upon its use a systematic comparative analysis of the effects of the 70 gene signature the Saint Continued Frequency and Cost of Chemotherapy Related Serious Adverse Effects in a Population

    Original URL path: http://www.agendia.com/category/cost-effectiveness/ (2016-05-01)
    Open archived version from archive

  • Development | Agendia
    new generation of diagnostic tools Publication Name BMC Genomics Author s Robert A Ach Arno Floore Bo Curry Vladimir Lazar Annuska M Glas Rob Pover Anya Tsalenko Hugues Ripoche Fatima Cardoso Mahasti Saghatchian d Assignies Laurakay Bruhn and Laura J Van t Veer June 7 2007 Background The increasing use of DNA microarrays in biomedical research toxicogenomics pharmaceutical development and diagnostics has focused attention on the reproducibility and reliability of microarray measurements While the reproducibility of microarray gene expression measurements has been the subject of several Continued Converting a breast cancer microarray signature into a high throughput diagnostic test Publication Name BMC Genomics Author s Glas AM Floore A Delahaye LJMJ et al October 30 2006 Background A 70 gene tumor expression profile was established as a powerful predictor of disease outcome in young breast cancer patients This profile however was generated on microarrays containing 25 000 60 mer oligonucleotides that are not designed for processing of many samples Continued Molecular Portraits and 70 Gene Prognosis Signature Are Preserved throughout the Metastatic Process of Breast Cancer Publication Name The Journal of Cancer Research Author s Britta Weigelt Zhiyuan Hu Xiaping He Chad Livasy Lisa A Carey Matthew G Ewend Annuska M Glas Charles M Perou and Laura J van t Veer January 1 2005 Microarray analysis has been shown to improve risk stratification of breast cancer Breast tumors analyzed by hierarchical clustering of expression patterns of intrinsic genes have been reported to subdivide into at least four molecular subtypes that are associated with distinct Continued A Gene Expression Signature as a Predictor of Survival in Breast Cancer Publication Name New England Journal of Medicine Author s Marc J van de Vijver M D Ph D Yudong D He Ph D Laura J van t Veer Ph D Hongyue Dai Ph

    Original URL path: http://www.agendia.com/category/development/ (2016-05-01)
    Open archived version from archive



  •